Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Amyotrophic Lateral Sclerosis and the Innate Immune System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02869048
Recruitment Status : Recruiting
First Posted : August 16, 2016
Last Update Posted : October 6, 2017
Sponsor:
Collaborators:
Zealand University Hospital
Bispebjerg Hospital
Aarhus University Hospital
Odense University Hospital
Information provided by (Responsible Party):
Anne-Lene Kjældgaard, Rigshospitalet, Denmark

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 2026
Estimated Study Completion Date : June 2026
Publications:
Conradi, S. Cytotoxic factor in plasma from ALS patients provokes haemolysis of normal erythrocytes. Acta Neurologica Scandinavica, 65: 246-247, 1982
Ronnevi, LO., Conradi, S. and Karlsson, E. Cytotoxic effect of immunoglobulins in Amyotrophic Lateral Sclerosis (ALS). Acta Neurologica Scandinavica, 69: 182-183, 1984
Armitage P BG. Statistical Methods for Medical Researchers. Blackwell1994.